Successful Combination Therapy of Radical Liver Resection With 5-Fluorouracil/leucovorin, Oxaliplatin, Plus Bevacizumab for Ascending Colon Cancer With Pulmonary and 43 Liver Metastases: Report of a Case

Ochiai, Takanori; Masuda, Taiki; Yagi, Masayuki; Kasai, Reo; Furuyama, Takaki; Tsukamoto, Kanako; Ito, Hiromitsu; Igari, Kimihiro; Aihara, Arihiro; Kumagai, Yoshito; Iida, Michio; Odajima, Hajime; Tanaka, Shinji; Arii, Shigeki; Yamazaki, Shigeru

doi:10.9738/cc88.1

Cited by 4 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Around 20-25% of patients initially diagnosed with colorectal carcinoma present with liver metastases ( 100 ). Of these, 80–90% have multiple organ metastasis, including liver, and 50% have exclusively liver metastasis ( 101 ).…”

Section: Liver Metastasesmentioning

confidence: 99%

Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses

Chen

2022

Front. Med.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most devastating diseases that accounts for numerous deaths worldwide. Tumor cell-autonomous pathways, such as the oncogenic signaling activation, significantly contribute to CRC progression and metastasis. Recent accumulating evidence suggests that the CRC microenvironment also profoundly promotes or represses this process. As the roles of the tumor microenvironment (TME) in CRC progression and metastasis is gradually uncovered, the importance of these non-cell-autonomous signaling pathways is appreciated. However, we are still at the beginning of this TME function exploring process. In this review, we summarize the current understanding of the TME in CRC progression and metastasis by focusing on the gut microbiota and host cellular and non-cellular components. We also briefly discuss TME-remodeling therapies in CRC.

show abstract

Section: Liver Metastasesmentioning

confidence: 99%

Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses

Chen

2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…The liver is the most common site of CRC metastasis and upwards of 25% of patients with colorectal cancer will have liver metastases at the time of initial diagnosis 52. For those with resectable disease, liver metastasectomy can be performed before, after, or simultaneously with the primary tumor resection, although the addition of neoadjuvant chemotherapy with surgery in otherwise acceptable liver resection candidates has been shown to mildly increase progression-free survival by 9% and can be given some consideration 53.…”

Section: Response To Treatment: Metastasesmentioning

confidence: 99%

“…The liver is the most common site of CRC metastasis and upwards of 25% of patients with colorectal cancer will have liver metastases at the time of initial diagnosis. 52 For those with resectable disease, liver metastasectomy can be performed before, after, or simultaneously with the primary tumor resection, although the addition of neoadjuvant chemotherapy with surgery in otherwise acceptable liver resection candidates has been shown to mildly increase progression-free survival by 9% and can be given some consideration. 53 It is important to remember that overall survival after liver resection is not related to the response to chemotherapy, but is largely a function of the original staging at time of initial diagnosis with a significantly higher five-year survival for those with Stage 1 or 2 disease versus those with Stage 3 or 4 disease (83.9% vs. 35.7%).…”

Section: Response To Treatment: Metastasesmentioning

confidence: 99%

“…The liver is the most common site of CRC metastasis and upwards of 25% of patients with colorectal cancer will have liver metastases at time of initial diagnosis. 52 Modern systemic chemotherapy now has response rates in excess of 50%, and in those that do not undergo resection, the median survival approaches 2 years. 60 In a recent study by Adam and associates, the pCR of liver metastases was associated with a 5-year overall survival of 76%.…”

Section: Watch and Wait: The Next Step For Select Rectal Cancers?mentioning

confidence: 99%

See 1 more Smart Citation

Future Directions for Monitoring Treatment Response in Colorectal Cancer

Walker¹,

Zwintscher²,

Johnson³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

Treatment of advanced colon and rectal cancer has significantly evolved with the introduction of neoadjuvant chemoradiation therapy so much that, along with more effective chemotherapy regimens, surgery has been considered unnecessary among some institutions for select patients. The tumor response to these treatments has also improved and ultimately has been shown to have a direct effect on prognosis. Yet, the best way to monitor that response, whether clinically, radiologically, or with laboratory findings, remains controversial. The authors' aim is to briefly review the options available and, more importantly, examine emerging and future options to assist in monitoring treatment response in cases of locally advanced rectal cancer and metastatic colon cancer.

show abstract

“…Colorectal cancer (CRC) is one of the most common malignant tumors in the world, and liver metastasis is the most common form of CRC metastasis ( 1 ). Studies have shown that liver metastasis can occur in ~20% of newly diagnosed CRC patients within half a year ( 2 , 3 ). In addition, >50% of patients with advanced CRC have a median survival of only 21.3 months ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of hematopoietic progenitor cells on the biological characteristics of colon cancer tumor stem cells

Guan¹,

Yang²,

Wu³

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Cancer stem cells (CSCs) are a type of tumor cell that are self-sustaining and can differentiate into several different types of cells. The present study aims to investigate the effect of hematopoietic progenitor cells (HPCs) on the biological behavior of colon CSCs (CCSCs) and to determine the underlying molecular mechanisms of liver metastasis in colorectal cancer. Methods Subsets of CCSCs were isolated from stem-like HCT116 cells and cocultured with CD133 + HPCs in vitro. Colony formation assay, and CCK-8 were used to assess the effects of HPCs on CCSC subsets. Invasive and migration assay were done to study the effects of HPCs mediated metastatic capacity of CCSC subsets. Expression of MMP-9, VEGF, E-cadherin and β-catenin was analyzed by qPCR and Western blotting. Results CCK-8 and colony formation assays showed that HPCs significantly promoted proliferation and colony formation of the CCSC subsets (P=0.031). HPCs also significantly enhanced the migration (P=0.011) and invasive capacity (P=0.001) of the CCSC subsets. Quantitative PCR showed that MMP-9 and VEGF expression in CCSC subsets were significantly upregulated (P=0.000 and P=0.005). Western blotting showed that MMP-9, VEGF and β-catenin expression in CCSC subsets were significantly upregulated (P=0.000, P=0.005, P=0.000). The protein expression levels of E-cadherin in the CCSC subsets was significantly downregulated (P=0.002). Conclusions CD133 + HPCs enhanced migration, invasion and proliferation of CCSC subsets in vitro .

show abstract

Successful Combination Therapy of Radical Liver Resection With 5-Fluorouracil/leucovorin, Oxaliplatin, Plus Bevacizumab for Ascending Colon Cancer With Pulmonary and 43 Liver Metastases: Report of a Case

Cited by 4 publications

References 30 publications

Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses

Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses

Future Directions for Monitoring Treatment Response in Colorectal Cancer

Effect of hematopoietic progenitor cells on the biological characteristics of colon cancer tumor stem cells

Contact Info

Product

Resources

About